Loading…
Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel
Background The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory disease coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new...
Saved in:
| Published in: | New England Journal of Medicine 2021-12 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Request full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c539t-e92a0704e12778cbc396ce257db8991353b8ef1adb006c3f051c762092a11af23 |
|---|---|
| cites | |
| container_end_page | |
| container_issue | |
| container_start_page | |
| container_title | New England Journal of Medicine |
| container_volume | |
| creator | Pilishvili, Tamara Gierke, Ryan Fleming-Dutra, Katherine E Farrar, Jennifer L Mohr, Nicholas M Talan, David A Krishnadasan, Anusha Harland, Karisa K Smithline, Howard A Hou, Peter C Lee, Lilly C Lim, Stephen C Moran, Gregory J Krebs, Elizabeth Steele, Mark T Beiser, David G Faine, Brett Haran, John P Nandi, Utsav Schrading, Walter A Chinnock, Brian Henning, Daniel J Lovecchio, Frank Lee, Jane Barter, Devra Brackney, Monica Fridkin, Scott K Marceaux-Galli, Kaytlynn Lim, Sarah Phipps, Erin C Dumyati, Ghinwa Pierce, Rebecca Markus, Tiffanie M Anderson, Deverick J Debes, Amanda K Lin, Michael Y Mayer, Jeanmarie Kwon, Jennie H Safdar, Nasia Fischer, Marc Singleton, Rosalyn Chea, Nora Magill, Shelley S Verani, Jennifer R Schrag, Stephanie J |
| description | Background The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory disease coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new vaccines in a real-world setting. Methods We conducted a test-negative case–control study involving health care personnel across 25 U.S. states. Cases were defined on the basis of a positive polymerase-chain-reaction (PCR) or antigen-based test for SARS-CoV-2 and at least one Covid-19–like symptom. Controls were defined on the basis of a negative PCR test for SARS-CoV-2, regardless of symptoms, and were matched to cases according to the week of the test date and site. Using conditional logistic regression with adjustment for age, race and ethnic group, underlying conditions, and exposures to persons with Covid-19, we estimated vaccine effectiveness for partial vaccination (assessed 14 days after receipt of the first dose through 6 days after receipt of the second dose) and complete vaccination (assessed ≥7 days after receipt of the second dose). Results The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer–BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age ( |
| doi_str_mv | 10.1056/NEJMoa2106599 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_COVID</sourceid><recordid>TN_cdi_proquest_journals_2575129460</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2575129460</sourcerecordid><originalsourceid>FETCH-LOGICAL-c539t-e92a0704e12778cbc396ce257db8991353b8ef1adb006c3f051c762092a11af23</originalsourceid><addsrcrecordid>eNotjbFOwzAUAL0woMLIbok54T27tuOxikILaguiLWvlOM8QlNqQpP1-IsF0090xdoeQIyj9sK2eN8kJBK2svWbLKgTyY3uhSMPAU-Cnt-2Cl-nSNhla_u68byNxd0rxgx_yXc5X5Lrxk5euJ_5K_ZBipO6GXQXXDXT7zxk7PFb7cpWtX5ZP5WKdeSXtmJEVDgzMCYUxha-9tNqTUKapC2tRKlkXFNA1NYD2MoBCb7SASUN0QcgZu__rfvfp50zDePxK5z5Oy-NUUSjsXIP8BTO8RL0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2575129460</pqid></control><display><type>article</type><title>Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel</title><source>Coronavirus Research Database</source><creator>Pilishvili, Tamara ; Gierke, Ryan ; Fleming-Dutra, Katherine E ; Farrar, Jennifer L ; Mohr, Nicholas M ; Talan, David A ; Krishnadasan, Anusha ; Harland, Karisa K ; Smithline, Howard A ; Hou, Peter C ; Lee, Lilly C ; Lim, Stephen C ; Moran, Gregory J ; Krebs, Elizabeth ; Steele, Mark T ; Beiser, David G ; Faine, Brett ; Haran, John P ; Nandi, Utsav ; Schrading, Walter A ; Chinnock, Brian ; Henning, Daniel J ; Lovecchio, Frank ; Lee, Jane ; Barter, Devra ; Brackney, Monica ; Fridkin, Scott K ; Marceaux-Galli, Kaytlynn ; Lim, Sarah ; Phipps, Erin C ; Dumyati, Ghinwa ; Pierce, Rebecca ; Markus, Tiffanie M ; Anderson, Deverick J ; Debes, Amanda K ; Lin, Michael Y ; Mayer, Jeanmarie ; Kwon, Jennie H ; Safdar, Nasia ; Fischer, Marc ; Singleton, Rosalyn ; Chea, Nora ; Magill, Shelley S ; Verani, Jennifer R ; Schrag, Stephanie J</creator><creatorcontrib>Pilishvili, Tamara ; Gierke, Ryan ; Fleming-Dutra, Katherine E ; Farrar, Jennifer L ; Mohr, Nicholas M ; Talan, David A ; Krishnadasan, Anusha ; Harland, Karisa K ; Smithline, Howard A ; Hou, Peter C ; Lee, Lilly C ; Lim, Stephen C ; Moran, Gregory J ; Krebs, Elizabeth ; Steele, Mark T ; Beiser, David G ; Faine, Brett ; Haran, John P ; Nandi, Utsav ; Schrading, Walter A ; Chinnock, Brian ; Henning, Daniel J ; Lovecchio, Frank ; Lee, Jane ; Barter, Devra ; Brackney, Monica ; Fridkin, Scott K ; Marceaux-Galli, Kaytlynn ; Lim, Sarah ; Phipps, Erin C ; Dumyati, Ghinwa ; Pierce, Rebecca ; Markus, Tiffanie M ; Anderson, Deverick J ; Debes, Amanda K ; Lin, Michael Y ; Mayer, Jeanmarie ; Kwon, Jennie H ; Safdar, Nasia ; Fischer, Marc ; Singleton, Rosalyn ; Chea, Nora ; Magill, Shelley S ; Verani, Jennifer R ; Schrag, Stephanie J</creatorcontrib><description>Background The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory disease coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new vaccines in a real-world setting. Methods We conducted a test-negative case–control study involving health care personnel across 25 U.S. states. Cases were defined on the basis of a positive polymerase-chain-reaction (PCR) or antigen-based test for SARS-CoV-2 and at least one Covid-19–like symptom. Controls were defined on the basis of a negative PCR test for SARS-CoV-2, regardless of symptoms, and were matched to cases according to the week of the test date and site. Using conditional logistic regression with adjustment for age, race and ethnic group, underlying conditions, and exposures to persons with Covid-19, we estimated vaccine effectiveness for partial vaccination (assessed 14 days after receipt of the first dose through 6 days after receipt of the second dose) and complete vaccination (assessed ≥7 days after receipt of the second dose). Results The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer–BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age (<50 years or ≥50 years), race and ethnic group, presence of underlying conditions, and level of patient contact. Estimates of vaccine effectiveness were lower during weeks 9 through 14 than during weeks 3 through 8 after receipt of the second dose, but confidence intervals overlapped widely. Conclusions The BNT162b2 and mRNA-1273 vaccines were highly effective under real-world conditions in preventing symptomatic Covid-19 in health care personnel, including those at risk for severe Covid-19 and those in racial and ethnic groups that have been disproportionately affected by the pandemic. (Funded by the Centers for Disease Control and Prevention.)</description><identifier>DOI: 10.1056/NEJMoa2106599</identifier><language>eng</language><publisher>Waltham: Massachusetts Medical Society</publisher><subject>COVID-19 vaccines</subject><ispartof>New England Journal of Medicine, 2021-12</ispartof><rights>2021. Not withstanding the ProQuest Terms and Conditions, you may use this content in accordance with the associated terms available at https://www.nejm.org/about-nejm/permissions?query=footer</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c539t-e92a0704e12778cbc396ce257db8991353b8ef1adb006c3f051c762092a11af23</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2575129460?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>783,787,27939,38530,43909</link.rule.ids><linktorsrc>$$Uhttps://www.proquest.com/docview/2575129460?pq-origsite=primo$$EView_record_in_ProQuest$$FView_record_in_$$GProQuest</linktorsrc></links><search><creatorcontrib>Pilishvili, Tamara</creatorcontrib><creatorcontrib>Gierke, Ryan</creatorcontrib><creatorcontrib>Fleming-Dutra, Katherine E</creatorcontrib><creatorcontrib>Farrar, Jennifer L</creatorcontrib><creatorcontrib>Mohr, Nicholas M</creatorcontrib><creatorcontrib>Talan, David A</creatorcontrib><creatorcontrib>Krishnadasan, Anusha</creatorcontrib><creatorcontrib>Harland, Karisa K</creatorcontrib><creatorcontrib>Smithline, Howard A</creatorcontrib><creatorcontrib>Hou, Peter C</creatorcontrib><creatorcontrib>Lee, Lilly C</creatorcontrib><creatorcontrib>Lim, Stephen C</creatorcontrib><creatorcontrib>Moran, Gregory J</creatorcontrib><creatorcontrib>Krebs, Elizabeth</creatorcontrib><creatorcontrib>Steele, Mark T</creatorcontrib><creatorcontrib>Beiser, David G</creatorcontrib><creatorcontrib>Faine, Brett</creatorcontrib><creatorcontrib>Haran, John P</creatorcontrib><creatorcontrib>Nandi, Utsav</creatorcontrib><creatorcontrib>Schrading, Walter A</creatorcontrib><creatorcontrib>Chinnock, Brian</creatorcontrib><creatorcontrib>Henning, Daniel J</creatorcontrib><creatorcontrib>Lovecchio, Frank</creatorcontrib><creatorcontrib>Lee, Jane</creatorcontrib><creatorcontrib>Barter, Devra</creatorcontrib><creatorcontrib>Brackney, Monica</creatorcontrib><creatorcontrib>Fridkin, Scott K</creatorcontrib><creatorcontrib>Marceaux-Galli, Kaytlynn</creatorcontrib><creatorcontrib>Lim, Sarah</creatorcontrib><creatorcontrib>Phipps, Erin C</creatorcontrib><creatorcontrib>Dumyati, Ghinwa</creatorcontrib><creatorcontrib>Pierce, Rebecca</creatorcontrib><creatorcontrib>Markus, Tiffanie M</creatorcontrib><creatorcontrib>Anderson, Deverick J</creatorcontrib><creatorcontrib>Debes, Amanda K</creatorcontrib><creatorcontrib>Lin, Michael Y</creatorcontrib><creatorcontrib>Mayer, Jeanmarie</creatorcontrib><creatorcontrib>Kwon, Jennie H</creatorcontrib><creatorcontrib>Safdar, Nasia</creatorcontrib><creatorcontrib>Fischer, Marc</creatorcontrib><creatorcontrib>Singleton, Rosalyn</creatorcontrib><creatorcontrib>Chea, Nora</creatorcontrib><creatorcontrib>Magill, Shelley S</creatorcontrib><creatorcontrib>Verani, Jennifer R</creatorcontrib><creatorcontrib>Schrag, Stephanie J</creatorcontrib><title>Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel</title><title>New England Journal of Medicine</title><description>Background The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory disease coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new vaccines in a real-world setting. Methods We conducted a test-negative case–control study involving health care personnel across 25 U.S. states. Cases were defined on the basis of a positive polymerase-chain-reaction (PCR) or antigen-based test for SARS-CoV-2 and at least one Covid-19–like symptom. Controls were defined on the basis of a negative PCR test for SARS-CoV-2, regardless of symptoms, and were matched to cases according to the week of the test date and site. Using conditional logistic regression with adjustment for age, race and ethnic group, underlying conditions, and exposures to persons with Covid-19, we estimated vaccine effectiveness for partial vaccination (assessed 14 days after receipt of the first dose through 6 days after receipt of the second dose) and complete vaccination (assessed ≥7 days after receipt of the second dose). Results The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer–BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age (<50 years or ≥50 years), race and ethnic group, presence of underlying conditions, and level of patient contact. Estimates of vaccine effectiveness were lower during weeks 9 through 14 than during weeks 3 through 8 after receipt of the second dose, but confidence intervals overlapped widely. Conclusions The BNT162b2 and mRNA-1273 vaccines were highly effective under real-world conditions in preventing symptomatic Covid-19 in health care personnel, including those at risk for severe Covid-19 and those in racial and ethnic groups that have been disproportionately affected by the pandemic. (Funded by the Centers for Disease Control and Prevention.)</description><subject>COVID-19 vaccines</subject><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><recordid>eNotjbFOwzAUAL0woMLIbok54T27tuOxikILaguiLWvlOM8QlNqQpP1-IsF0090xdoeQIyj9sK2eN8kJBK2svWbLKgTyY3uhSMPAU-Cnt-2Cl-nSNhla_u68byNxd0rxgx_yXc5X5Lrxk5euJ_5K_ZBipO6GXQXXDXT7zxk7PFb7cpWtX5ZP5WKdeSXtmJEVDgzMCYUxha-9tNqTUKapC2tRKlkXFNA1NYD2MoBCb7SASUN0QcgZu__rfvfp50zDePxK5z5Oy-NUUSjsXIP8BTO8RL0</recordid><startdate>20211216</startdate><enddate>20211216</enddate><creator>Pilishvili, Tamara</creator><creator>Gierke, Ryan</creator><creator>Fleming-Dutra, Katherine E</creator><creator>Farrar, Jennifer L</creator><creator>Mohr, Nicholas M</creator><creator>Talan, David A</creator><creator>Krishnadasan, Anusha</creator><creator>Harland, Karisa K</creator><creator>Smithline, Howard A</creator><creator>Hou, Peter C</creator><creator>Lee, Lilly C</creator><creator>Lim, Stephen C</creator><creator>Moran, Gregory J</creator><creator>Krebs, Elizabeth</creator><creator>Steele, Mark T</creator><creator>Beiser, David G</creator><creator>Faine, Brett</creator><creator>Haran, John P</creator><creator>Nandi, Utsav</creator><creator>Schrading, Walter A</creator><creator>Chinnock, Brian</creator><creator>Henning, Daniel J</creator><creator>Lovecchio, Frank</creator><creator>Lee, Jane</creator><creator>Barter, Devra</creator><creator>Brackney, Monica</creator><creator>Fridkin, Scott K</creator><creator>Marceaux-Galli, Kaytlynn</creator><creator>Lim, Sarah</creator><creator>Phipps, Erin C</creator><creator>Dumyati, Ghinwa</creator><creator>Pierce, Rebecca</creator><creator>Markus, Tiffanie M</creator><creator>Anderson, Deverick J</creator><creator>Debes, Amanda K</creator><creator>Lin, Michael Y</creator><creator>Mayer, Jeanmarie</creator><creator>Kwon, Jennie H</creator><creator>Safdar, Nasia</creator><creator>Fischer, Marc</creator><creator>Singleton, Rosalyn</creator><creator>Chea, Nora</creator><creator>Magill, Shelley S</creator><creator>Verani, Jennifer R</creator><creator>Schrag, Stephanie J</creator><general>Massachusetts Medical Society</general><scope>COVID</scope></search><sort><creationdate>20211216</creationdate><title>Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel</title><author>Pilishvili, Tamara ; Gierke, Ryan ; Fleming-Dutra, Katherine E ; Farrar, Jennifer L ; Mohr, Nicholas M ; Talan, David A ; Krishnadasan, Anusha ; Harland, Karisa K ; Smithline, Howard A ; Hou, Peter C ; Lee, Lilly C ; Lim, Stephen C ; Moran, Gregory J ; Krebs, Elizabeth ; Steele, Mark T ; Beiser, David G ; Faine, Brett ; Haran, John P ; Nandi, Utsav ; Schrading, Walter A ; Chinnock, Brian ; Henning, Daniel J ; Lovecchio, Frank ; Lee, Jane ; Barter, Devra ; Brackney, Monica ; Fridkin, Scott K ; Marceaux-Galli, Kaytlynn ; Lim, Sarah ; Phipps, Erin C ; Dumyati, Ghinwa ; Pierce, Rebecca ; Markus, Tiffanie M ; Anderson, Deverick J ; Debes, Amanda K ; Lin, Michael Y ; Mayer, Jeanmarie ; Kwon, Jennie H ; Safdar, Nasia ; Fischer, Marc ; Singleton, Rosalyn ; Chea, Nora ; Magill, Shelley S ; Verani, Jennifer R ; Schrag, Stephanie J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c539t-e92a0704e12778cbc396ce257db8991353b8ef1adb006c3f051c762092a11af23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>COVID-19 vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pilishvili, Tamara</creatorcontrib><creatorcontrib>Gierke, Ryan</creatorcontrib><creatorcontrib>Fleming-Dutra, Katherine E</creatorcontrib><creatorcontrib>Farrar, Jennifer L</creatorcontrib><creatorcontrib>Mohr, Nicholas M</creatorcontrib><creatorcontrib>Talan, David A</creatorcontrib><creatorcontrib>Krishnadasan, Anusha</creatorcontrib><creatorcontrib>Harland, Karisa K</creatorcontrib><creatorcontrib>Smithline, Howard A</creatorcontrib><creatorcontrib>Hou, Peter C</creatorcontrib><creatorcontrib>Lee, Lilly C</creatorcontrib><creatorcontrib>Lim, Stephen C</creatorcontrib><creatorcontrib>Moran, Gregory J</creatorcontrib><creatorcontrib>Krebs, Elizabeth</creatorcontrib><creatorcontrib>Steele, Mark T</creatorcontrib><creatorcontrib>Beiser, David G</creatorcontrib><creatorcontrib>Faine, Brett</creatorcontrib><creatorcontrib>Haran, John P</creatorcontrib><creatorcontrib>Nandi, Utsav</creatorcontrib><creatorcontrib>Schrading, Walter A</creatorcontrib><creatorcontrib>Chinnock, Brian</creatorcontrib><creatorcontrib>Henning, Daniel J</creatorcontrib><creatorcontrib>Lovecchio, Frank</creatorcontrib><creatorcontrib>Lee, Jane</creatorcontrib><creatorcontrib>Barter, Devra</creatorcontrib><creatorcontrib>Brackney, Monica</creatorcontrib><creatorcontrib>Fridkin, Scott K</creatorcontrib><creatorcontrib>Marceaux-Galli, Kaytlynn</creatorcontrib><creatorcontrib>Lim, Sarah</creatorcontrib><creatorcontrib>Phipps, Erin C</creatorcontrib><creatorcontrib>Dumyati, Ghinwa</creatorcontrib><creatorcontrib>Pierce, Rebecca</creatorcontrib><creatorcontrib>Markus, Tiffanie M</creatorcontrib><creatorcontrib>Anderson, Deverick J</creatorcontrib><creatorcontrib>Debes, Amanda K</creatorcontrib><creatorcontrib>Lin, Michael Y</creatorcontrib><creatorcontrib>Mayer, Jeanmarie</creatorcontrib><creatorcontrib>Kwon, Jennie H</creatorcontrib><creatorcontrib>Safdar, Nasia</creatorcontrib><creatorcontrib>Fischer, Marc</creatorcontrib><creatorcontrib>Singleton, Rosalyn</creatorcontrib><creatorcontrib>Chea, Nora</creatorcontrib><creatorcontrib>Magill, Shelley S</creatorcontrib><creatorcontrib>Verani, Jennifer R</creatorcontrib><creatorcontrib>Schrag, Stephanie J</creatorcontrib><collection>Coronavirus Research Database</collection><jtitle>New England Journal of Medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Pilishvili, Tamara</au><au>Gierke, Ryan</au><au>Fleming-Dutra, Katherine E</au><au>Farrar, Jennifer L</au><au>Mohr, Nicholas M</au><au>Talan, David A</au><au>Krishnadasan, Anusha</au><au>Harland, Karisa K</au><au>Smithline, Howard A</au><au>Hou, Peter C</au><au>Lee, Lilly C</au><au>Lim, Stephen C</au><au>Moran, Gregory J</au><au>Krebs, Elizabeth</au><au>Steele, Mark T</au><au>Beiser, David G</au><au>Faine, Brett</au><au>Haran, John P</au><au>Nandi, Utsav</au><au>Schrading, Walter A</au><au>Chinnock, Brian</au><au>Henning, Daniel J</au><au>Lovecchio, Frank</au><au>Lee, Jane</au><au>Barter, Devra</au><au>Brackney, Monica</au><au>Fridkin, Scott K</au><au>Marceaux-Galli, Kaytlynn</au><au>Lim, Sarah</au><au>Phipps, Erin C</au><au>Dumyati, Ghinwa</au><au>Pierce, Rebecca</au><au>Markus, Tiffanie M</au><au>Anderson, Deverick J</au><au>Debes, Amanda K</au><au>Lin, Michael Y</au><au>Mayer, Jeanmarie</au><au>Kwon, Jennie H</au><au>Safdar, Nasia</au><au>Fischer, Marc</au><au>Singleton, Rosalyn</au><au>Chea, Nora</au><au>Magill, Shelley S</au><au>Verani, Jennifer R</au><au>Schrag, Stephanie J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel</atitle><jtitle>New England Journal of Medicine</jtitle><date>2021-12-16</date><risdate>2021</risdate><abstract>Background The prioritization of U.S. health care personnel for early receipt of messenger RNA (mRNA) vaccines against severe acute respiratory disease coronavirus 2 (SARS-CoV-2), the virus that causes coronavirus disease 2019 (Covid-19), allowed for the evaluation of the effectiveness of these new vaccines in a real-world setting. Methods We conducted a test-negative case–control study involving health care personnel across 25 U.S. states. Cases were defined on the basis of a positive polymerase-chain-reaction (PCR) or antigen-based test for SARS-CoV-2 and at least one Covid-19–like symptom. Controls were defined on the basis of a negative PCR test for SARS-CoV-2, regardless of symptoms, and were matched to cases according to the week of the test date and site. Using conditional logistic regression with adjustment for age, race and ethnic group, underlying conditions, and exposures to persons with Covid-19, we estimated vaccine effectiveness for partial vaccination (assessed 14 days after receipt of the first dose through 6 days after receipt of the second dose) and complete vaccination (assessed ≥7 days after receipt of the second dose). Results The study included 1482 case participants and 3449 control participants. Vaccine effectiveness for partial vaccination was 77.6% (95% confidence interval [CI], 70.9 to 82.7) with the BNT162b2 vaccine (Pfizer–BioNTech) and 88.9% (95% CI, 78.7 to 94.2) with the mRNA-1273 vaccine (Moderna); for complete vaccination, vaccine effectiveness was 88.8% (95% CI, 84.6 to 91.8) and 96.3% (95% CI, 91.3 to 98.4), respectively. Vaccine effectiveness was similar in subgroups defined according to age (<50 years or ≥50 years), race and ethnic group, presence of underlying conditions, and level of patient contact. Estimates of vaccine effectiveness were lower during weeks 9 through 14 than during weeks 3 through 8 after receipt of the second dose, but confidence intervals overlapped widely. Conclusions The BNT162b2 and mRNA-1273 vaccines were highly effective under real-world conditions in preventing symptomatic Covid-19 in health care personnel, including those at risk for severe Covid-19 and those in racial and ethnic groups that have been disproportionately affected by the pandemic. (Funded by the Centers for Disease Control and Prevention.)</abstract><cop>Waltham</cop><pub>Massachusetts Medical Society</pub><doi>10.1056/NEJMoa2106599</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | DOI: 10.1056/NEJMoa2106599 |
| ispartof | New England Journal of Medicine, 2021-12 |
| issn | |
| language | eng |
| recordid | cdi_proquest_journals_2575129460 |
| source | Coronavirus Research Database |
| subjects | COVID-19 vaccines |
| title | Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-02T11%3A17%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_COVID&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20mRNA%20Covid-19%20Vaccine%20among%20U.S.%20Health%20Care%20Personnel&rft.jtitle=New%20England%20Journal%20of%20Medicine&rft.au=Pilishvili,%20Tamara&rft.date=2021-12-16&rft_id=info:doi/10.1056/NEJMoa2106599&rft_dat=%3Cproquest_COVID%3E2575129460%3C/proquest_COVID%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c539t-e92a0704e12778cbc396ce257db8991353b8ef1adb006c3f051c762092a11af23%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2575129460&rft_id=info:pmid/&rfr_iscdi=true |